UroGen (URGN) Director Wen Leana Receives 18,000 Share Awards

What Happened
Wen Leana, a director of UroGen Pharma Ltd. (URGN), received equity awards on 2026-06-22: a grant of 10,000 option-based shares and 8,000 restricted stock units (RSUs). Both awards were recorded at $0.00 (no cash paid). Together the grants total 18,000 derivative awards that will convert to ordinary shares only as they vest.

Key Details

• Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely, not marked late).
• Awards: 10,000 option-based units (derivative) and 8,000 RSUs (derivative); grant price reported $0.00.
• Vesting: both awards vest in equal quarterly installments over one year, subject to Continuous Service (see footnotes).
• RSU note: each RSU represents a contingent right to one ordinary share upon vesting.
• Shares owned after transaction: not specified in the filing.

Context

• These are awards/grants (not open-market purchases or sales). Options give the right to acquire shares in the future; RSUs convert to shares upon vesting.
• Awards issued to directors are common for compensation and retention; they do not by themselves indicate a purchase or sale sentiment.